CliffBio
small molecule

ISENTRESS

RALTEGRAVIR POTASSIUM

Loss of exclusivityJune 2030latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Drug detail

Brand nameISENTRESS
Active ingredientRALTEGRAVIR POTASSIUM
StrengthEQ 400MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2007
Marketing statusRX

Listed patents

PatentExpiresType
8771733June 2030substance, product
7754731*PEDSeptember 2029—
7754731March 2029substance, product
8852632January 2028substance, product

More from MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ISENTRESS patent cliff — loss of exclusivity June 2030 | CliffBio